Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evofem BiosciencesEVFM -3.03% Equity-to-Asset is -11.64 as of Jun. 2026. The stock has 5 warning signs investors should review. Among 1,414 Biotechnology companies, Evofem Biosciences ranks worse than 98.59% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Evofem Biosciences's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $-87.52 Mil. Evofem Biosciences's Total Assets for the quarter that ended in Jun. 2026 was $7.52 Mil.
Therefore, Evofem Biosciences's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was -11.64.
The historical rank and industry rank for Evofem Biosciences's Equity-to-Asset or its related term are showing as below:
EVFM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -25.22 Med: -2.25 Max: 0.93
Current: -11.64
During the past 13 years, the highest Equity to Asset Ratio of Evofem Biosciences was 0.93. The lowest was -25.22. And the median was -2.25.
EVFM's Equity-to-Asset is ranked worse than 98.59% of 1414
companies
in the Biotechnology industry
Industry Median: 0.69
vs EVFM: -11.64
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Evofem Biosciences Equity-to-Asset Related Terms
Evofem Biosciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Evofem Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVFM vs BZYR, ZVSA, RMTG: Equity-to-Asset Comparison
For the Biotechnology subindustry, Evofem Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evofem Biosciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Evofem Biosciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Evofem Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evofem Biosciences (EVFM) has a Equity-to-Asset of -11.64 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Evofem Biosciences and its competitors. According to the industry distribution chart, Evofem Biosciences ranks #1394 out of 1414 companies in the Biotechnology industry, placing it in the top 98.6%.
Is Evofem Biosciences' Equity-to-Asset too high?
Evofem Biosciences' current Equity-to-Asset is -11.64. Based on the distribution chart, Evofem Biosciences ranks #1394 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Evofem Biosciences' Equity-to-Asset compare to BZYR and ZVSA?
According to the Biotechnology industry distribution chart, Evofem Biosciences ranks #1394 out of 1414 companies for Equity-to-Asset. This places Evofem Biosciences in the lower half of its industry. The industry median Equity-to-Asset is 0.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Evofem Biosciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evofem Biosciences's current Equity-to-Asset is -11.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 20% below its estimated fair value. The current Equity-to-Asset is -11.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Equity-to-Asset is -11.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVFM has been successfully added to your 
